These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 21371510)
21. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356 [TBL] [Abstract][Full Text] [Related]
22. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery. Wang SH; Thompson AL; Hickey AJ; Staats HF Curr Top Microbiol Immunol; 2012; 354():121-56. PubMed ID: 21822816 [TBL] [Abstract][Full Text] [Related]
28. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791 [TBL] [Abstract][Full Text] [Related]
29. Dry coating of immunotherapeutics to densely packed and short microprojection arrays. Park K J Control Release; 2009 Nov; 139(3):171. PubMed ID: 19735682 [No Abstract] [Full Text] [Related]
34. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Amorij JP; Saluja V; Petersen AH; Hinrichs WL; Huckriede A; Frijlink HW Vaccine; 2007 Dec; 25(52):8707-17. PubMed ID: 17996993 [TBL] [Abstract][Full Text] [Related]
35. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? Bal SM; Ding Z; van Riet E; Jiskoot W; Bouwstra JA J Control Release; 2010 Dec; 148(3):266-82. PubMed ID: 20869998 [TBL] [Abstract][Full Text] [Related]
36. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248 [TBL] [Abstract][Full Text] [Related]
37. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Widera G; Johnson J; Kim L; Libiran L; Nyam K; Daddona PE; Cormier M Vaccine; 2006 Mar; 24(10):1653-64. PubMed ID: 16246466 [TBL] [Abstract][Full Text] [Related]
38. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828 [TBL] [Abstract][Full Text] [Related]
39. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926 [TBL] [Abstract][Full Text] [Related]